Learn Before
Findings opposed to use of Azithromycin+Hydroxychloroquine as COVID-19 intervention
Findings about use of Azithromycin as COVID-19 intervention from study of hospitalized patients in New York City
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Amongst random sample of 1438 hospitalized, laboratory-confirmed COVID-19 cases across metropolitan New York City, in-hospital mortality was not significantly different for those treated with with hydroxychloroquine (Hazard ratio (HR)=1.08 [95% confidence interval (CI)= 0.63-1.85]), azithromycin (HR=0.56 [95% CI= 0.26-1.21]), or both (HR=1.35 [95% CI= 0.76-2.40]).
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Findings from a Systematic Review and Meta-Analysis on the Effect of Hydroxychloroquine With or Without Azithromycin on the Mortality of COVID-19 Patients
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Methods for determining odds of cardiac arrest amongst hospitalized COVID-19 patients in New York City given Azithromycin, Hydroxychloroquine, or a combination
Hazard ratio for time to in-hospital mortality amongst hospitalized COVID-19 patients in New York City were not significantly different for those given Azithromycin, Hydroxychloroquine, or a combination
Proportion of abnormal ECG findings in hospitalized COVID-19 patients in New York City were higher amongst those who received Azithromycin+Hydroxychloroquine and Hydroxychloroquine